Authors observated the effect of moxibustion on changes of 5-HT and immunefunction of rat infected with EHFV.The results show that moxibustion could enhance the phago-cytosis of peritoneal macrophage of rat infected w...Authors observated the effect of moxibustion on changes of 5-HT and immunefunction of rat infected with EHFV.The results show that moxibustion could enhance the phago-cytosis of peritoneal macrophage of rat infected with EHFV,increase the roset rate of RBC C<sub>3</sub>brecptor,decrease the content of 5-HT in plasma.There is a significant dffeerence between EHFVinfected group and moxibustion group.That suggests the moxibustion could enhance the immunefunction of body,regulate the metablic disturbance of 5-HT in plasma,maintain the internal en-vironment of body and enhance the force of body to anti EHFV.Maybe that can play an impor-tant role in the mechanism of moxibustion treating EHF.展开更多
Alzheimer’s disease (AD) is a progressive neurological disorder primarily affecting new memory formation as well as retrieval of previously acquired memories. According to World Health Organization, current global po...Alzheimer’s disease (AD) is a progressive neurological disorder primarily affecting new memory formation as well as retrieval of previously acquired memories. According to World Health Organization, current global population suffering from cognitive impairment is estimated to 37 million. The number is projected to double in next one and half decade. Half of the population afflicted with dementia is represented by AD patients. Current therapies, which provide marginal symptomatic relief to AD patients, are effective only in half of the patient population. In depth understanding of the molecular mechanism of the disease is urgently required to develop more effective therapies. Therapies in clinical development may either offer symptomatic relief to patients or provide pure disease modifications, thus limiting benefit to patients. 5-HT4 receptor agonists offer an attractive option for the treatment of AD patients. Activation of 5- HT4 receptor under preclinical conditions is demonstrated to improve neurotransmission and enhance the release of acetylcholine resulting in the memory formation. In various cell based and animal models, partial 5-HT4 receptor agonists are demonstrated to promote the release of soluble amyloid precursor protein alpha and block the release of amyloid beta peptide offering suitable candidates as disease modification agents. Remarkably, 5-HT4 receptor agonists are also reported to induce neurogenesis in hippocampus as well as enteric system through the activation of cyclic AMP response element binding protein in rodents. Taken together, 5-HT4 agonists address all major facets of Alzheimer’s disease and may provide therapeutic potential for other neurological disorders.展开更多
文摘Authors observated the effect of moxibustion on changes of 5-HT and immunefunction of rat infected with EHFV.The results show that moxibustion could enhance the phago-cytosis of peritoneal macrophage of rat infected with EHFV,increase the roset rate of RBC C<sub>3</sub>brecptor,decrease the content of 5-HT in plasma.There is a significant dffeerence between EHFVinfected group and moxibustion group.That suggests the moxibustion could enhance the immunefunction of body,regulate the metablic disturbance of 5-HT in plasma,maintain the internal en-vironment of body and enhance the force of body to anti EHFV.Maybe that can play an impor-tant role in the mechanism of moxibustion treating EHF.
文摘Alzheimer’s disease (AD) is a progressive neurological disorder primarily affecting new memory formation as well as retrieval of previously acquired memories. According to World Health Organization, current global population suffering from cognitive impairment is estimated to 37 million. The number is projected to double in next one and half decade. Half of the population afflicted with dementia is represented by AD patients. Current therapies, which provide marginal symptomatic relief to AD patients, are effective only in half of the patient population. In depth understanding of the molecular mechanism of the disease is urgently required to develop more effective therapies. Therapies in clinical development may either offer symptomatic relief to patients or provide pure disease modifications, thus limiting benefit to patients. 5-HT4 receptor agonists offer an attractive option for the treatment of AD patients. Activation of 5- HT4 receptor under preclinical conditions is demonstrated to improve neurotransmission and enhance the release of acetylcholine resulting in the memory formation. In various cell based and animal models, partial 5-HT4 receptor agonists are demonstrated to promote the release of soluble amyloid precursor protein alpha and block the release of amyloid beta peptide offering suitable candidates as disease modification agents. Remarkably, 5-HT4 receptor agonists are also reported to induce neurogenesis in hippocampus as well as enteric system through the activation of cyclic AMP response element binding protein in rodents. Taken together, 5-HT4 agonists address all major facets of Alzheimer’s disease and may provide therapeutic potential for other neurological disorders.
